Drug intelligence / Profile preview

tofimilast

Development stage: Phase 2
Lead developer: Merck KGaA
Modality: Small Molecules
Administration: Oral

Overview

Tofimilast is a selective phosphodiesterase-4 (PDE4) inhibitor developed for the treatment of inflammatory airway diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. As a PDE4 inhibitor, tofimilast works by increasing intracellular cyclic adenosine monophosphate (cAMP) levels in immune and structural cells, leading to reduced inflammation in the airways. Tofimilast is structurally related to other PDE4 inhibitors like roflumilast but is a distinct chemical entity. It has been investigated primarily for its anti-inflammatory effects in respiratory conditions.

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on tofimilast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tofimilast.

Explore the full profile